Please assess the completion status of the following clinical trial:

Trial Title: Combined 18F-NaF/18F-FDG PET/MRI for Detection of Skeletal Metastases

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
All patients were enrolled after receiving a regular medical care bone scan using the radiolabel 99mTc-methyl diphosphonate (t99-MDP).~INCLUSION CRITERIA~* ≥ 18 years old at the time of the drug administration~* ≥ Stage 3 breast cancer OR ≥ stage 2 prostate cancer OR prostate-specific antigen (PSA) \> 10 micrograms/L OR recurrent breast or prostate cancer~* Capable of complying with study procedures~* Able to remain still for duration of imaging procedure (about one hour)~* Written informed consent~EXCLUSION CRITERIA~* Pregnant or nursing~* Metallic implants that contraindicate MRI~* Renal function impairment that contraindicates MRI

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort 1 Pilot-WB-MRI & Combined 18F-NaF-CT/18F-FDG-PET scans (Type: EXPERIMENTAL): Preliminary pilot assessment to confirm feasibility \& improved diagnostic accuracy of the combined 18F-NaF CT \& 18F-FDG PET scan procedures, as compared to the regular medical care procedure, 99mTc MDP bone scans.
- Cohort 2 WB-MRI & Combined 18F-NaF-CT/18F-FDG-PET scans (Type: EXPERIMENTAL): Assessment to define the accuracy of the combined 18F-NaF CT \& 18F-FDG PET/CT scan procedures compared to 99mTc MDP bone scan.
- Cohort 3 Combined 18F-NaF / 18F-FDG PET/WB-MRI scan (Type: EXPERIMENTAL): Assessment to define the utility of 18F-NaF \& 18F-FDG as the radiolabels in a single combined PET / WB-MRI procedure.

Based on this trial design, predict the completion outcome and termination type (if applicable).